title: Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility genes for bipolar disorder.
abstract: Attempts to map susceptibility genes for bipolar disorder have been complicated by genetic complexity of the illness and, above all by heterogeneity. This paper reviews the genetic research of bipolar disorder aiming to reduce the heterogeneity by focusing on definite responders to long-term lithium treatment. The available evidence strongly suggests that lithium-responsive bipolar disorder is the core bipolar phenotype, characterized by a more prominent role of genetic factors. Responders to lithium have typically a family history of bipolar disorder (often responsive to lithium). They differ from responders to other mood stabilizing drugs in their family histories as well as in other clinical characteristics. The molecular genetic investigations of bipolar disorder responsive to lithium indicate possibly several loci linked to and/or associated with the illness. A combination of research strategies employing multiple methods such as linkage, association, and gene-expression studies will be needed to clarify which of these represent true susceptibility loci.
authors.affiliation: Department of Psychiatry, Dalhousie University, 5909 Jubilee Road, Halifax, Nova Scotia, Canada B3H 2E2. malda@dal.ca
authors.forename: Martin
authors.initials: M
authors.lastname: Alda
authors.forename: Paul
authors.initials: P
authors.lastname: Grof
authors.forename: Guy A
authors.initials: GA
authors.lastname: Rouleau
authors.forename: Gustavo
authors.initials: G
authors.lastname: Turecki
authors.forename: L Trevor
authors.initials: LT
authors.lastname: Young
mesh_terms: D018692:Antimanic Agents / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005820:Genetic Testing / Q000379:methods; D006801:Humans; D008094:Lithium / Q000627:therapeutic use*
chemical_list: D018692:Antimanic Agents; D008094:Lithium